Skip to content

MDMA: all studies

Page 201 of 345: studies 2,001 to 2,010 of 3,446, newest first. Back to the MDMA overview

Research

Effect of 3,4‐Methylenedioxymethamphetamine on 3,4‐Dihydroxyphenylalanine Accumulation in the Striatum and Nucleus Accumbens

Journal of Neurochemistry March 1, 1990 J. Frank Nash, Herbert Y. Meltzer, Gary A. Gudelsky

Abstract: The effect of the racemic mixture of 3,4‐methy‐lenedioxymethamphetamine (MDMA) on the synthesis of dopamine in the terminals of nigrostriatal and mesolimbic neurons was estimated by measuring the accumulation of 3,4‐dihydroxyphenylalanine (DOPA) in the striatum and nucleus accumbens 30 min following the administration of the l‐aromatic amino acid decarboxylase inhibitor,...

Second Thoughts on 3,4-Methylenedioxymethamphetamine (MDMA) Neurotoxicity

Archives of General Psychiatry March 1, 1990 Charles S. Grob 34 citations

To the Editor.— Recent attention has been drawn to the purported neurotoxic dangers associated with 3, 4-methylenedioxymethamphetamine (MDMA). Price et al1have attempted to assess possible serotonergic neurotransmitter damage by contrasting serum prolactin response to the challenge with intravenous L-tryptophan in subjects with a history of MDMA use vs control subjects. Their primary finding...

5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents.

European Journal of Pharmacology February 20, 1990 C. R. Hekmatpanah, S. Peroutka

This study examined the [3H]5-HT-releasing properties of 3,4-methylenedioxymethamphetamine (MDMA) and related agents, all of which cause significant release of [3H]5-HT from rat brain synaptosomes. 5-HT uptake blockers dose dependently block MDMA-induced [3H]5-HT release. The EC50s of the uptake drugs in blocking MDMA-induced release correlate with their affinity for the 5-HT uptake site...

MDMA (ecstasy) effects on cultured serotonergic neurons: evidence for Ca2+-dependent toxicity linked to release

Brain Research February 1, 1990 E.C. Azmitia, R.B. Murphy, P.M. Whitaker-Azmitia 68 citations

Animal studies have established a correlation between release of 5-hydroxytryptamine (5-HT) and the long-term reduction of 5-HT (toxicity) by 3,4-methylenedioxymethamphetamine (MDMA) with the S(+) enantiomer being more active than the R(-). Using a microculture system of fetal raphe neurons, the enantiomers of MDMA were tested to determine if a similar difference in potency existed. The results...

5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa.

Journal of Pharmacology and Experimental Therapeutics 1990 C. J. Schmidt, Vicki L. Taylor, Gina M. Abbate et al.

The active and inactive stereoisomers of the serotonin (5-HT2) antagonist, MDL 11,939, were used to examine the relationship between the acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on the dopaminergic system and its long-term effects on the serotonergic system. Only the R-(+) stereoisomer of MDL 11,939 both reversed the acute stimulation of striatal dopamine synthesis by MDMA and...

Reduction of [3H]6-nitroquipazine-labelled 5-hydroxytryptamine uptake sites in rat brain by 3,4-methylenedioxymethamphetamine.

Fundamental and Clinical Pharmacology 1990 Kenji Hashimoto, Tsuyoshi Goromaru

3,4-Methylenedioxymethamphetamine (MDMA; Ecstasy) is a known neurotoxin to 5-hydroxytryptamine (5-HT; serotonin) nerve terminals. It has recently been demonstrated that [3H]6-nitroquipazine is a new radioligand for studying the 5-HT transport system in brain. Therefore, we examined the effects of repeated systemic administration (10 mg/kg ip, twice daily for 3 d) of MDMA on...

Human Deaths and Toxic Reactions Attributed to MDMA and MDEA

Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA 1990 Graeme P. Dowling 24 citations

3,4-Methylenedioxymethamphetamine (MDMA) and 3,4- Methylenedioxyethamphetamine (MDEA) are synthetic amphetamine analogues that have received considerable media attention as recreational drugs popular among college students and young professionals. MDMA, more commonly known as “Ecstasy,” has been available on the illicit drug market since 1968 (1). with increasing popularity in the late 1970s...

DOI: 10.1007/978-1-4613-1485-1_5 (opens in new tab) Full text (opens in new tab) Psychoactive drug Toxic reaction Multiple injury Idiosyncratic reaction +1

History of MDMA

Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA 1990 Alexander T. Shulgin 35 citations

There can never be a complete history of any intensely controversial topic whose proponents and skeptics state their beliefs with equal confidence. Some historical facts will rest uncontested. Many facts will be clothed in opinions that will color the way the facts are to be interpreted. Other facts will never be publicly known, for reasons of legality or privacy. And some facts may simply be...

DOI: 10.1007/978-1-4613-1485-1_1 (opens in new tab) Full text (opens in new tab) Psychoactive drug Control substance Optical isomer Methyl ketone +1

Structure-Activity Relationships of MDMA and Related Compounds: A New Class of Psychoactive Agents?

Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA 1990 David F. Nichols, Robert Oberlender 6 citations

It has been hypothesized that MDMA and substances that possess a psychopharmacological effect similar to MDMA are members of a novel pharmacological class named entactogens [1–3]. In this chapter evidence will be presented to support this, through a discussion of the data acquired in efforts directed toward testing this hypothesis. Although these studies are far from complete, the results...

DOI: 10.1007/978-1-4613-1485-1_7 (opens in new tab) Full text (opens in new tab) Drug discrimination Training dose Complete substitution Discriminative stimulus property

Stereoselective pharmacokinetics of 3,4‐methylenedioxymethamphetamine in the rat

Chirality 1990 Robert L. Fitzgerald, Robert V. Blanke, Alphonse Poklis 50 citations

Abstract Studies to characterize the pharmacokinetics of the enantiomers of MDMA were conducted in rats using the iliac arterial cannulation. Two routes of administration, intravenous and subcutaneous, were evaluated at two dose levels for each route [20 and 40 mg/kg (±)‐MDMA for subcutaneous, 10 and 20 mg/kg (±)‐MDMA for intravenous administrations]. The average half‐life (±SD) for all dosing...